PMID- 15500401
OWN - NLM
STAT- MEDLINE
DCOM- 20051209
LR  - 20191026
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 4
IP  - 11
DP  - 2004 Nov
TI  - Recent clinical development of dendritic cell-based immunotherapy for prostate 
      cancer.
PG  - 1729-34
AB  - Dendritic cells (DCs) are the most powerful immune cells that present antigens to 
      T cells, resulting in a T cell response. Therapeutic strategies involving DCs 
      have been explored in many malignancies, including prostate cancer. These 
      strategies are designed to stimulate DC proliferation, promote antigen uptake and 
      processing by DCs, or to directly provide antigen-loaded DCs. All approaches are 
      designed to stimulate an antitumour T cell response leading to clinical benefit. 
      Many approaches in prostate cancer have demonstrated successful induction of the 
      desired immune response. Clinical effect has also been observed, prompting larger 
      definitive trials.
FAU - Rini, Brian
AU  - Rini B
AD  - UCSF Comprehensive Cancer Center, 1600 Divisidero, 3rd floor, San Francisco, CA 
      94115, USA. brini@medicine.ucsf.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Membrane Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (flt3 ligand protein)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adenocarcinoma/*therapy
MH  - Antigen Presentation
MH  - Antigens, Neoplasm/genetics/immunology
MH  - Clinical Trials as Topic
MH  - Dendritic Cells/drug effects/*immunology/transplantation
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/administration & 
      dosage/pharmacology/*therapeutic use
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Immunotherapy, Adoptive
MH  - Male
MH  - Membrane Proteins/therapeutic use
MH  - Multicenter Studies as Topic
MH  - Prostate-Specific Antigen/genetics
MH  - Prostatic Neoplasms/*therapy
MH  - RNA, Messenger/genetics
MH  - Randomized Controlled Trials as Topic
MH  - Salvage Therapy
MH  - T-Lymphocyte Subsets/immunology
MH  - Transfection
MH  - Treatment Outcome
RF  - 18
EDAT- 2004/10/27 09:00
MHDA- 2005/12/13 09:00
CRDT- 2004/10/27 09:00
PHST- 2004/10/27 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2004/10/27 09:00 [entrez]
AID - EBT041102 [pii]
AID - 10.1517/14712598.4.11.1729 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2004 Nov;4(11):1729-34. doi: 10.1517/14712598.4.11.1729.